Author

Peng-Fei Jin

h-index 5 View on Semantic Scholar

We have 3 of 29 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Sep 2026

Dissociation between humoral and multi-omic immune responses to inactivated COVID-19 vaccination in patients with pulmonary tuberculosis

Despite comparable short-term neutralizing antibody responses, PTB patients receiving anti-tuberculosis treatment exhibited attenuated and distinct systems-level proteomic and transcriptomic remodeling after inactivated COVID-19 vaccination compared with healthy controls, suggesting a predominance of nominal negative a...

Zhi-Jie Jiang, Peng-Fei Jin, Xiao-Rui Nie et al. · Frontiers in Immunology · 0 citations

Clinical trial Open access Aug 2026

The efficacy, immunogenicity and safety of the LZ901 vaccine for herpes zoster virus in adults 40 years of age or older: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

LZ901 reduces the risk of herpes zoster in adults who were 40 years of age or older in 12 months, with a favorable safety profile, and reports that the vaccine reduces the risk of viral infection and has favorable safety profiles.

Peng-Fei Jin, Ya-Ru Quan, Xue Gao et al. · Nature Communications · 0 citations

Open access Jul 2026

Systemic immune profiling of heterologous versus homologous boosting of COVID-19 vaccination.

Heterologous boosting with Ad5-nCoV elicited more mature B cells with higher affinity and activated more abundant immune-related pathways compared to the homologous boosting with CoronaVac, which gives insights for elaborating the systemic immune landscape of heterologous-boosting COVID-19 immunization by the novel sin...

Xu Han, Hudachuan Jiang, Hui Zheng et al. · Journal of Translational Med... · 0 citations